Tactile dose marking for accessible doses for the blind and visually impaired via small-scale 3D printing - solid dose forms are distinguishable by size, color, and shape: most are small, white, and…

Active Grant Awarded

Award ID
90BISA0102
Recipient
Awarding agency
Obligated
$100,000

Award facts

Completion date 32% complete
Place of performance
Hagerstown, MD, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Administration for Community Living awarded Infratrac Inc. $100,000 in obligated grant funding on September 23, 2026, under the ACL National Institute on Disability, Independent Living, and Rehabilitation Research program (CFDA 93.433). The program supports research to improve the lives of people with physical and mental disabilities.

Infratrac is developing tactile dose markings for solid dose forms made through small-scale 3D drug printing, so that blind and visually impaired patients can identify medications by touch. The work will print doses with tactile markings, some paired with high-contrast coloring, and present them to blind and visually impaired testers to determine which are best distinguished by touch. The deliverables are marked samples, vetted for scale-up potential, that succeeded in user testing. The stated objectives also include demonstrating a set of tested differentiator markings to the commercial marketplace. The Applied Pharmaceutics Laboratory at the University of Maryland, Baltimore is an implementation partner, and the Carroll Center for the Blind and the Maryland Department of Disabilities Assistive Technology Program (MDTAP) guide the work. Anticipated outcomes include improved medication management independence, lesser caregiver burden, and better adherence and health outcomes.

Infratrac is a woman-owned small business. The award's ultimate completion date is March 29, 2027, and the place of performance is Hagerstown, MD.

Description

Tactile dose marking for accessible doses for the blind and visually impaired via small-scale 3D printing - solid dose forms are distinguishable by size, color, and shape: most are small, white, and round. Many feature printed letters or numbers. These visual identification cues are of little use to blind and visually impaired patients. Infratrac, INC., a woman-owned small business innovator, in partnership with the applied pharmaceutics laboratory at the university of maryland, baltimore and guided by the carroll center for the blind and the maryland department of disabilities assistive technology program (MDTAP), will use 3D drug printing to optimize doses for accessibility. Current approaches are limited. "talking labels" and large print focus on the container and offer no help to the patient once the medication is removed from its original packaging. The goal of this investigation: use 3D drug printing to generate accessible doses, using tactile markings, some paired with high-contrast coloring. By presenting the accessible doses to blind and visually impaired testers, the researchers can assess which are best distinguished by touch. The objectives are to 1) demonstrate the viability of improving drug identification across populations who will benefit from this approach, including the blind and visually impaired, some of them elderly, 2) use the versatility of 3D drug printing to optimize tactile and high-contrast markings, and 3) demonstrate to the commercial marketplace a set of well-tested differentiator markings that are compatible with scale-up. Anticipated outcomes include improved medication management independence and lesser burden on caregivers. Improvements in medication adherence, and consequent improvement in health outcomes, are also anticipated. The products of this research will be the marked samples, vetted for scale-up potential, that have succeeded in user testing.

Quick answers

Who received award 90BISA0102?

90BISA0102 was awarded to Infratrac Inc. by National Institute on Disability Independent Living and Rehabilitation Research (Administration for Community Living) on September 23, 2026.

How much is award 90BISA0102 worth?

$100,000 has been obligated on 90BISA0102.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award